da Costa Miranda V, de Souza Fede AB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, de Paula Carvalho J, Filho EA, de Freitas D, Del Pilar Estevez M, Diz. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol. 2014;132:287–91.

Article  PubMed  Google Scholar 

Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol. 2013;128:6–11.

Article  PubMed  Google Scholar 

Shah MM, Landen CN. Ovarian cancer stem cells: are they real and why are they important? Gynecol Oncol. 2014;132:483–9.

Article  PubMed  Google Scholar 

Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett. 2012;322(1):1–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah MM, Landen CN. Ovarian cancer stem cells: Are they real and why are they important? Gynecol Oncol. 2013. https://doi.org/10.1016/j.ygyno.2013.12.001.

Article  PubMed  PubMed Central  Google Scholar 

Kozlowska AK, Topchyan P, Kaur K, Tseng HC, Teruel A, Hiraga T, Jewett A. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer. 2017;8:537–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grossenbacher SK, Canter RJ, Murphy WJ. Natural killer cell immunotherapy to target stem-like tumor cells. J Immunother Cancer. 2016;4:19.

Article  PubMed  PubMed Central  Google Scholar 

Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother. 2009;58:641–52.

Article  CAS  PubMed  Google Scholar 

Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3:781–90.

Article  CAS  PubMed  Google Scholar 

Vyas M, Reinartz S, Hoffmann N, Reiners KS, Lieber S, Jansen JM, Wagner U, Muller R, von Strandmann EP. Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation. Oncoimmunology. 2017;6:e1339854.

Article  PubMed  PubMed Central  Google Scholar 

Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S. Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. Cell Mol Immunol. 2014;11:495–502.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoogstad-van Evert JS, Bekkers R, Ottevanger N, Jansen JH, Massuger L, Dolstra H. Harnessing natural killer cells for the treatment of ovarian cancer. Gynecol Oncol. 2020;157:810–6.

Article  CAS  PubMed  Google Scholar 

Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ke M, Wang H, Zhou Y, Li J, Liu Y, Zhang M, Dou J, Xi T, Shen B, Zhou C. SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice. Oncotarget. 2016;7:49509–26.

Article  PubMed  PubMed Central  Google Scholar 

Takeda K, Suyama H, Igishi T, Shigeoka Y, Matsumoto S, Yamasaki A, Hashimoto K, Sumikawa T, Morita M, Ueda Y, Shimizu E. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells. Oncol Rep. 2008;19:945–51.

CAS  PubMed  Google Scholar 

Fukushima M, Sakamoto K, Ohshimo H, Nakagawa F, Taguchi T. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. Oncol Rep. 2010;24:835–42.

Article  CAS  PubMed  Google Scholar 

Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Williston Park). 1998;12:19–22.

CAS  PubMed  Google Scholar 

Campos MP, Konecny GE. The target invites a foe: antibody-drug conjugates in gynecologic oncology. Curr Opin Obstet Gynecol. 2018;30:44–50.

Article  PubMed  Google Scholar 

Malekshah OM, Sarkar S, Nomani A, Patel N, Javidian P, Goedken M, Polunas M, Louro P, Hatefi A. Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis. J Control Release. 2019;311–312:273–87.

Article  PubMed  PubMed Central  Google Scholar 

Nouri FS, Wang X, Hatefi A. Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. J Control Release. 2015;200:179–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karjoo Z, Chen X, Hatefi A. Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev. 2016;99:113–28.

Article  CAS  PubMed  Google Scholar 

Malekshah OM, Chen X, Nomani A, Sarkar S, Hatefi A. Enzyme/prodrug systems for cancer gene therapy. Current pharmacol reports. 2016;2:299–308.

Article  CAS  Google Scholar 

Sarkar S, Malekshah OM, Nomani A, Patel N, Hatefi A. A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer. Cancer Med. 2018;7:3630–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nociari MM, Shalev A, Benias P, Russo C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods. 1998;213:157–67.

Article  CAS  PubMed  Google Scholar 

Fan J, Shi J, Zhang Y, Liu J, An C, Zhu H, Wu P, Hu W, Qin R, Yao D, Shou X, Xu Y, Tong Z, Wen X, Xu J, Zhang J, Fang W, Lou J, Yin W, Chen W. NKG2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes. EMBO J. 2022;41:e107739.

Article  CAS  PubMed  Google Scholar 

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fane A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Walchli S. NK cells specifically TCR-dressed to kill cancer cells. EBioMedicine. 2019;40:106–17.

Article  PubMed  PubMed Central  Google Scholar 

Maki G, Klingemann HG, Martinson JA, Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res. 2001;10:369–83.

Article  CAS  PubMed  Google Scholar 

Klymenko Y, Wates RB, Weiss-Bilka H, Lombard R, Liu Y, Campbell L, Kim O, Wagner D, Ravosa MJ, Stack MS. Modeling the effect of ascites-induced compression on ovarian cancer multicellular aggregates. Dis Model Mech. 2018. https://doi.org/10.1242/dmm.034199.

Article  PubMed  PubMed Central  Google Scholar 

Auer K, Bachmayr-Heyda A, Aust S, Grunt TW, Pils D. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Cancer Lett. 2017;388:158–66.

Article  CAS  PubMed  Google Scholar 

Torigoe S, Ogata Y, Matono K, Shirouzu K. Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells. Anticancer Res. 2009;29:2083–9.

CAS  PubMed  Google Scholar 

Wang D, Zou L, Jin Q, Hou J, Ge G, Yang L. Human carboxylesterases: a comprehensive review. Acta Pharm Sin B. 2018;8:699–712.

Article  PubMed  PubMed Central  Google Scholar 

Matsumoto K, Katsumata N, Yamanaka Y, Yonemori K, Kohno T, Shimizu C, Andoh M, Fujiwara Y. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol. 2006;100:412–6.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Chen N, Yu Y, Zhou L, Niu C, Liu Y, Tian H, Lv Z, Han F, Cui J. Prognostic value of MICA/B in cancers: a systematic review and meta-analysis. Oncotarget. 2017;8:96384–95.

Article  PubMed  PubMed Central  Google Scholar 

Schmiedel D, Mandelboim O. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy. Front Immunol. 2018;9:2040.

Article  PubMed  PubMed Central  Google Scholar 

Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123–33.

Article  CAS  PubMed  Google Scholar